Mohamad Mohty
Onco
Daily
Twitter
Facebook
Youtube
RSS Feed
Linkedin
Facebook
RSS
Twitter
Youtube
Linkedin
July, 2024
July 2024
M
T
W
T
F
S
S
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
« Jun
Mohamad Mohty
May 27, 2024, 03:45 |
Blog
Joshua Richter: Beyond honored to be working with giants of myeloma
Joshua Richter, Associate Professor of Medicine in The Tisch Cancer Institute, Division of Hematology and Medical…
Jan 21, 2024, 15:31 |
Blog
Humaid Al-Shamsi: I was honored to meet with our role models and world expert in BMT, Mohamad Mohty and Ali Bazarbashi
Humaid Al-Shamsi, Director of Burjeel Cancer Institute (BCI) Comprehensive Cancer Center, shared a post on…
Jan 11, 2024, 18:11 |
Blog
Amer Zeidan: Dr Mohamad Mohty continues to lead high value educational initiatives globally and in Middle East
Amer Zeidan, Associate Professor of Hematology at Yale University, shared a post on LinkedIn: "Dr Mohamad…
Dec 24, 2023, 16:02 |
Blog
Mohamad Mohty: Getting ready for «the mission»
Mohamad Mohty, Professor of Hematology at Sorbonne University, and Head of the Clinical Hematology and…
Oct 25, 2023, 17:36 |
Blog
Naveen Pemmaraju: Shout out to my fellow co-founding moderators for the successful first-in-person MPN Co&D meeting in Paris.
Naveen Pemmaraju shared on Twitter: "Shout out to my fellow co-founding moderators for the successful…
Oct 11, 2023, 19:22 |
Blog
Naveen Pemmaraju: I was honored to Co-Chair the Inaugural in-person MPNCo and D Meeting October 2023 with Prof Ruben Mesa, MD and Prof Claire Harrison this week in Paris, France
Jul 7, 2023, 06:06 |
Blog
This is a nice example showing that academic and commercial CAR-T cells can co-exist - Mohamad Mohty
This is a nice example showing that academic and commercial CAR-T cells can co-exist. Congratulations…
1
2
All:
17
Posts:
11 - 20
We need to hurry up, because cancer and patients cannot wait!
Eliot Levitt: The Yvonne Awards demonstrate something that it doesn't hurt to be reminded of
New data from the NEST clinical trial was presented at ESMOGI24 - Agenus
Zainab Shinkafi-Bagudu's latest commentary on Cervical Cancer Elimination Forum
New Paper Alert! Amivantamab-Lazertinib Improves Outcomes in High-Risk EGFR-Mutant NSCLC Subgroups: MARIPOSA Study Results
Facebook
RSS Feed
Twitter
Linkedin
Youtube